



RNS: RELEASE

28 June 2024

Immupharma PLC
("Immupharma" or the "Company")

2024 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

Immupharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below.

Resolution	For	% For	Against	% Against	Withheld
1. To receive the accounts of the Company for the year ended 31 December 2023 together with the reports thereon of the directors and auditors of the Company	86,062,471	100%	2,400	0.00%	11,950
2. To re-appoint Dr Laurence Reilly as a director of the Company	80,641,856	97.22%	2,305,727	2.78%	3,129,241
3. To re-appoint Dr Sebastian Goudreau as a director of the Company	82,355,053	97.28%	2,305,727	2.72%	1,416,044
4. To re-appoint Lisa Baderoon as a director of the Company	82,357,053	97.28%	2,305,727	2.72%	1,414,044
5. To re-appoint CLA Evelyn Partners Limited as Auditor of the Company	81,844,124	97.25%	2,318,324	2.75%	1,914,376
6. That the Directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting	81,127,174	95.26%	4,040,309	4.74%	909,338
SPECIAL RESOLUTION 7. That, subject to the passing of Resolution 6 the directors be and they are hereby empowered pursuant to section 571 of the Act to allot equity securities as set out in the Notice of Meeting	81,127,174	95.26%	4,040,309	4.74%	909,338

As at the date of the AGM, the number of issued ordinary shares of the Company was 416,437,265 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Ends

For further information please contact:

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer and Chairman
Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

+44 (0) 203 368 3550

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

+44 (0) 203 650 3650/51

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 is a first-in class autophagy immunomodulator for the treatment of Lupus and CIDP and preclinical analysis suggests P140 may have therapeutic benefit in many other autoimmune diseases that are caused by the same dysfunction in the immune system.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGMZGZVMRFGDZM